Dilon Technologies

Focus: Dilon Technologies is a newly founded (2024) biotechnology company specializing in probes and imaging devices based in Newport News, VA. The company operates as a pre-revenue biotech with no disclosed funding or employee count.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Dilon Technologies

AI assessmentNot Hiring

No open roles listed right now. Follow Dilon Technologies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MarginProbe2.0

Breast Cancer

N/A

Clinical Trials (1)

NCT05377229MarginProbe 2.0 Data Collection Protocol

N/A

Help build intelligence for Dilon Technologies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape company culture and technical direction from inception in a specialized imaging/probe technology space
Potential for significant equity upside if the company secures funding and achieves clinical or commercial validation
Focused niche market (probes and imaging devices) may offer less competition and clearer IP differentiation than crowded therapeutic areas

Watch Out For

Company is only 1 year old with no disclosed funding, revenue, or employee count—financial runway and long-term viability are completely unvalidated
Zero active clinical programs, no products, and no publications suggest the company is in stealth mode or very early stage, creating high execution risk
No hiring activity detected and no public information on leadership, advisory board, or operational capacity raises questions about actual operational status

Generated by Claude from Dilon Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

HEMOBLAST™ Bellows

Surgical Bleeding

N/A

Clinical Trials (1)

NCT04734535Evaluation of Safety of HEMOBLAST Bellows in Spine Surgery

N/A

Hemoblast Bellows application

Excessive Bleeding During Surgery

Phase 4

Clinical Trials (1)

NCT06511778sTErnAl heMostasiS Trial

Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline